Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial
Key facts
- Who runs it
- University of Florida
- Where
- Gainesville, United StatesSee the site
- Trial code
- Status
- Not yet recruiting
- People taking part
- 1,296 people, planned
- Starts
- 15 Sept 2027
- Expected to end
- 15 Sept 2028
- Type of study
- Interventional, 5 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Protect Me 4 Application + External Quality Improvement Support
- Protect Me 4 Application Alone
- Record updated
- 14 September 2026
Who can take part
- Age
- 18 years to 99 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Must be parent of an adolescent aged 11-12 years old
- Providers working with age appropriate for study adolescents at the intervention clinics
- Adolescents/Parents/Providers willing to consent to participation
- Adolescents/Parents that can read and speak English
Who cannot take part
- Adolescents out of the age range for participation
- Adolescents/Parents/Providers unwilling to consent to participation
- Adolescents/Parents that can NOT read and speak English
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Where in United States
- University of FloridaGainesville, United StatesContact: Stephanie Staras, PhDNot yet recruiting
About the trial
What the trial wants to find out
Human papillomavirus (HPV) vaccines have potential to prevent an average of 26,900 cancer cases each year in the United States, but vaccine coverage rates remain low. The study team has developed an electronic application (app), Protect Me 4, to help parents and providers assess and have more productive conversations about needed vaccines.
Read full original descriptionShow less
The specific aims of this study are to: (1) evaluate the feasibility of implementing Protect Me 4, and (2) estimate preliminary efficacy of Protect Me 4 to increase HPV vaccine initiation (receipt of first dose).
The 5 groups in the trial
- ParentsExisting treatment, for comparison
Parents of 11-12 year old children who visit participating interventional clinics during study period.
Treatment: Protect Me 4 Application + External Quality Improvement Support and Protect Me 4 Application Alone
- Health Care ProviderExisting treatment, for comparison
Health care providers and clinic staff for 11-12 year old patients at 4 participating pediatric clinics.
Treatment: Protect Me 4 Application + External Quality Improvement Support and Protect Me 4 Application Alone
- Adolescents at Intervention clinicsNo study treatment, for comparison
Adolescents between 11-12 years of age. Adolescent vaccination data is used in the study, adolescents will assent to participate. The parents, however, use the HIT system.
- Adolescents at Control ClinicNo study treatment, for comparison
Parents of 11-12 year old children who visit participating control clinics during study period.
- Health Care Provider at Control ClinicNo study treatment, for comparison
Health care providers and clinic staff for 11-12 year old patients at 3 participating pediatric control clinics.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT03429413, who can take part
- Record updated
- 14 September 2026